


CLAIMS:

1. A compound according to Formula (Ia):



wherein:


Q is phenylene substituted with one chloro;

Y is N;

R¹ is cyclopropyl or methyl;

R² and R³ are chloro;

R⁴-A is:



wherein the pyridylene is optionally substituted with one or two groups independently selected from halogen, C₁₋₄-alkoxy, halo-C₁₋₄-alkoxy, C₁₋₄-alkyl, and halo-C₁₋₄-alkyl and R⁴ is -CO₂R⁵ or -C(O)NR⁵R⁶;

R⁵ is hydrogen;

R⁶ is hydrogen or C₁₋₂-alkyl;

or pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

2. The compound of claim 1, wherein A is pyridylene substituted with one fluoro; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

3. The compound of claim 1, wherein A is unsubstituted pyridylene; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

4. The compound of claim 1 or 2, wherein R^4 is $-CO_2R^5$, and R^5 is hydrogen; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

5. The compound of claim 1 or 2, wherein:


R^4 is $-C(O)NR^5R^6$;

R^5 is hydrogen; and

R^6 is C_{1-2} -alkyl, wherein said C_{1-2} -alkyl is substituted with $-SO_3H$ or $-CO_2H$;


or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

6. The compound of claim 1 wherein R^4 -A is:




or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

7. A compound selected from the group consisting of:




or pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

8. A compound having the following formula:



or a pharmaceutically acceptable salt thereof.

9. A compound having the following formula:



10. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of any one of claims 1-9 and a pharmaceutically acceptable excipient.

11. Use of a compound or pharmaceutically acceptable salt thereof of any one of claims 1-9 for the manufacture of a medicament for the treatment of a FXR mediated condition.

12. The use of claim 11, wherein the FXR mediated condition is Non-Alcoholic Steatohepatitis (NASH).